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Abstract
Objectives
Perinatal hypoxic-ischemic brain injuries have been a major cause 
of mortality and neurodevelopmental morbidities in newborns. 
Citicoline and Piracetam have been used as nootropic agents in 
a number of studies. In this investigation, we aimed to determine 
the effects of these agents solely and in combination in hypoxic-
ischemic brain damage in rabbit neonates.
Materials & Methods
Hypoxic-ischemic brain damage was induced by the occlusion of 
both uterine arteries of dams for eight minutes. The subjects were 
randomly divided into five groups as follows (n=6 per group): 
control group without hypoxia (C1), control group with hypoxic-
ischemic damage (C2), the third group (P) received Piracetam (100 
mg/kg), the fourth group (T) administered with Citicoline (250 mg/
kg), and the fifth (PT) received both. The preventive effects of the 
two drugs on hypoxic-ischemic brain damage were microscopically 
investigated by the rates of damage to the hippocampus.
Results 
Neuronal destruction rates in C1, C2, P, T, and PT were 4%, 
45%, 37.5%, 12.5% (P=0.01 vs. C2), and 20% (P=0.03 vs. C2), 
respectively. The total means of hypoxic-ischemic damage, cell 
edema, neuronal degeneration, and eosinophilic degeneration were 
lower in the T group compared to C2 (P<0.05).  
Conclusion
According to our results and previous findings, Citicoline as a 
ORIGINAL ARTICLE
Comparison of the Effects of Citicoline and Piracetam on Hypoxic-ischemic Brain Damage in Neonatal Rabbits
How to Cite This Article: Ebrahimi S , Ashkani Esfahani S, Ebrahimi A. Comparison of the Effects of Citicoline and 
Piracetam on Hypoxic-ischemic Brain Damage in Neonatal Rabbits.  Iran J Child Neurol. Winter 2022; 16(1): 77-84
Sedigheh EBRAHIMI MD1, 
Soheil ASHKANI ESFAHANI MD2,
Alireza EBRAHIMI MD3
1. Department of Medical 
Ethics, Shiraz University of 
Medical Sciences, Shiraz, Iran
2. Department of Orthopaedic 
Surgery, Massachusetts General 
Hospital, Harvard Medical 
School, Boston, Massachusetts, 
USA
3. Student Research Committee, 




Student Research Committee, 







Comparison of the Effects of Citicoline and Piracetam on Hypoxic-ischemic Brain Damage in Neonatal Rabbits
Iran J Child Neurol. Winter 2022 Vol. 16 No. 1
Introduction
Hypoxic-ischemic (HI) brain injury is a condition 
that occurs when the brain components confront 
hypoxia, ischemia, and cytotoxicity (1). This 
disorder typically arises after cardiac arrest, 
respiratory arrest, incomplete suffocations, 
poisonous gas exposure, and perinatal asphyxia. 
Hypoxic-ischemic brain injury frequently produces 
symptoms such as disturbance of sensorimotor 
functions, seizure, and impairment of cognitive 
and emotional tasks (2, 3). The sequelae of the 
damage depend on the underlying mechanism, the 
severity, time course, and the duration of oxygen 
insufficiency and absence of bloodstream (1). 
Perinatal HI brain injuries, such as asphyxia, 
have been a major cause of mortality in newborn 
infants and chronic neurodevelopmental deficits 
in survivors (4). Investigations have reported that 
about 4 million newborns are affected by moderate 
to severe asphyxia in the developing countries, 20% 
of whom suffer from its sequelae, for example, HI 
encephalopathy (5, 6). However, hypoxic-ischemic 
encephalopathy (HIE) has a mortality rate of 
60%, and its treatment is now limited to intensive 
supportive care (7-9).
Citicoline is an intermediate complex molecule 
that involves several vital metabolic pathways 
(10, 11). Nutritional supplementation and 
intravenous administration of the agent have 
treatment for hypoxic-ischemic brain injuries could be beneficial, and 
it has priority over neuroprotective agents like Piracetam. Moreover, 
the combination of Citicoline and Piracetam showed no superior 
effect in contrast with Citicoline alone. However, experimental 
studies on larger populations and clinical trials are highly suggested.
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shown neuroprotective efficacy in stroke patients 
and elderly patients with cognitive problems, 
memory loss, and early stages of Alzheimer’s 
disease (12-14). Since a few decades ago, 
Piracetam has been advertised as a nootropic 
agent in several countries; the drug also has been 
used for the treatment of cognitive disorders, 
myoclonus, dyslexia, and vertigo (15, 16). The 
exact mechanism of Piracetam is yet to be cleared; 
however, there is growing evidence proving that the 
agent’s properties rely on the restoration of the cell 
membrane fluidity (15). Fixed dosage combination 
of Citocoline and Piracetam (500 mg and 800 mg) 
is also available in some markets and is used for 
memory enhancement, neurological and cognitive 
disorders, Parkinsonism, and Alzheimer’s disease 
(17). 
Considering the magnitude of the problem 
of HI brain injuries and the lack of accurate 
medication for the condition, it is appropriate for 
health-care professionals to give priority to the 
issue. Regarding therapeutic interventions and 
medications, animal studies are important for 
uncovering the underlying mechanisms of damages 
and the preventive roles of prescriptions. In this 
investigation, we aimed to determine the effects of 
the aforementioned neuroprotective agents solely 
and in the combination in HI brain-injured rabbits. 
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Materials & Methods 
Animal models 
Rabbits were chosen as the subjects of this 
experiment mainly due to similarities of their 
biology with human beings, the high rate of 
pregnancy, and the high numbers of newborns. 
Thirty pregnant New Zealand white rabbits, 
provided from the Animal Laboratory of Shiraz 
University of Medical Sciences, were randomly 
selected for the study. They were kept at 25±2°C 
temperature and in 60% humidity and regular 
light/dark cycle with adequate food and water for 
one week before the experiments. 
The models were randomly divided into five groups 
(n=6). The control group without any hypoxia-
ischemia (C1) and the control group with hypoxia-
ischemia (C2), which were killed immediately after 
inducing hypoxia, and their brain sections were 
used to ensure hypoxia induction and to evaluate 
the damages. For the third group (P), we prescribed 
Piracetam (800 mg, Daroupakhsh™, Iran) 100 mg/
kg of body weight orally seven days after inducing 
hypoxia-ischemia. The fourth group (T) received 
250 mg/kg of body weight Citicoline (250 mg, 
Alborzdarou™, Iran) intravenously once just after 
the hypoxia induction, then they were sacrificed 
on the seventh day. Finally, the fifth group (PT) 
received Piracetam (100 mg/kg) orally for a week 
as well as Citicoline (250 mg/kg) intravenously in 
a single dose as above.
Induction of hypoxic-ischemic brain damage
 Then, the clips were removed for 10 minutes 
to allow cerebral reperfusion while they were 
exposed to room air (21% oxygen), and then the 
fetuses were expulsed. The newborn rabbits were 
clinically evaluated to ensure their viability. (18)
1. Assessments
Alive neonates were sacrificed after 10 minutes 
of exposure to a high dose of pentobarbitone (1 
g, Specia™, France). The heads of the neonates 
were immersion fixed for two weeks in 10% 
paraformaldehyde in 0.1 M phosphate buffer. 
Therefore, the brains were systematically cut into 
4-mm thick coronal blocks of the hippocampus 
and were embedded in paraffin and sectioned at 
5-micron range with a vibrating microtome. To 
assess the destruction rate and to determine the 
presence of cellular hypoxia and degenerating 
neurons, the sections were stained with hematoxylin 
and eosin. Changes in Purkinje and pyramidal 
cells and necrosis, and edema in the damaged 
areas were determined under a light microscope 
(×400) by a pathologist who was blinded to the 
experimental groups. Analysis was performed by 
a light microscope, which showed Purkinje and 
pyramidal cells’ deformities as well as necrosis 
and edema in the studied regions. The preventive 
effects of the two drugs on hypoxia-ischemia were 
investigated by the rates of damage to hippocampal 
neurons.
2. Ethical considerations
All the experiments were performed according 
to the Guide for the Care and Use of Laboratory 
Animals (NIH publication No. 86-23, 1985 
edition) approved by the Ethics Committee of 
Shiraz University of Medical Sciences.
3. Statistical analysis
Histopathological scores were designed as median 
range and mean on graphs by GraphPad Prism 
software; also, they were analyzed using a non-
parametric Mann-Whitney U test by SPSS software 
(version 21.0, Chicago, IL, USA). A P-value of less 
than 0.05 was considered statistically significant.
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Results
Neuronal destruction in the C1 group was about 
4%, and the C2 group showed about 45% damage. 
In the T group, the rate of destruction was about 
12.5%, which was significantly lower than that of 
C2. The destruction rate of the P group was near 
37.5%, and the rate of destruction in the PT group 
was about 20-25% (Table 1). The results indicated 
that administrating intravenous Citicoline alone or 
in combination with Piracetam can decrease cell 
death in comparison to the untreated hypoxic-
ischemic brain-injured control group (P ≤ 0.05). 
Citocoline could also noticeably decline brain 
Table1. Intensity of the hypoxic-ischemic damage in the hippocampus of the rabbits of control group without any hypoxia (C1), con-
trol group with hypoxia (C2), experimental group with hypoxia treated with Piracetam (P), experimental group with hypoxia treated 
with Citicoline (T) and the experimental group with hypoxia treated with Piracetam and Citicoline (PT).

















* P≤0.05 vs. C2 group
† P≤0.05 vs. C1 group
edema (P ≤ 0.001) besides the total average 
of hypoxic-ischemic brain damage (P ≤ 0.05). 
Although the PT group showed a considerably 
lower damage of neuronal degeneration, the total 
average of hypoxic-ischemic damage in the P group 
and PT group was 36.3±4.42% and 27.9±10.94, 
respectively, which were not significantly different 
from that of the C2 group. Moreover, there was no 
significant reduction in the brain edema of the P 
and PT groups, and the degrees of brain edema 
were approximately near that of the control group 
(P > 0.05).
Discussion
Hypoxic-ischemic brain injury in general, and 
specifically, neonatal encephalopathy due to 
perinatal HI conditions are associates with 
high mortality, morbidity, and chronic lifelong 
disabilities (18). Currently, the treatment of HIE in 
newborns is limited to intensive supportive care, 
such as the reduction of whole-body temperature 
and brain temperature (9). However, reports have 
suggested that cell therapy and some drugs such 
as Alluporinol and Astragalus could be used in the 
case of perinatal HI brain damage (19-21). 
Our study showed that rabbit neonates who suffered 
from HI brain damage and were treated with 
Citocoline had a significantly lower degeneration 
and edema of neuronal cells besides lower total 
average HI destruction of the brain in comparison 
with the ones that did not receive the medication. 
81
Comparison of the Effects of Citicoline and Piracetam on Hypoxic-ischemic Brain Damage in Neonatal Rabbits
Iran J Child Neurol. Winter 2022 Vol. 16 No. 1
The results were consistent with the findings of a 
prior study performed by Rao et al., which showed 
that the drug had protective efficacy against blood-
brain barrier (BBB) dysfunction in the forebrain 
of gerbils. Başkaya et. al reported a significant 
reduction in brain edema and BBB breakdown after 
using the agent in rats affected by traumatic brain 
injury (22). Similar perinatal asphyxia models of 
rats indicated that the drug had a dose-dependent 
neuroprotective effect (23). Another study also 
supported the hypothesis of prescribing Citocoline 
for reducing the brain lesion growth produced 
by ischemic strokes by using diffusion-weighted 
magnetic resonance imaging (24). Investigations 
have reported that newborn nerve action (NBNA) 
scores in newborns suffering from HIE and gross 
motor function classification system (GMFCS) 
levels were improved after using the drug (25-26).
Piracetam and Piracetam-like drugs have a vast 
range of applications in neurological problems, for 
example, cognition/memory deficits, myoclonus 
epilepsy, ataxia, aphasia, chronic fatigue syndrome, 
and autism. A meta-analysis on animal models 
of stroke and cerebral ischemia also mentioned 
that the drug could have beneficial effects on the 
improvement of consequences (27). As our study 
demonstrated, Piracetam also had a neuroprotective 
effect by reducing average neuronal cell 
degeneration in rabbits’ hippocampus. However, 
no significant reduction was observed in BBB 
failure and cell edema of the specimen. A previous 
study on rats with chronic cerebral hypo-perfusion 
demonstrated that the agent could improve memory 
deficits and neuronal damages (28). Kessler et. al 
reported that Piracetam facilitated the recovery 
of verbal skills in post-stroke patients; they also 
showed a significant increase in task-related flow 
activation in the left hemisphere of the brain after 
using the medication (29). 
A combined tablet of Citocoline and Piracetam 
is recently introduced to the market for several 
neurologic problems. However, combined 
administration of the drugs decreased neuronal cell 
degeneration by 20%; there was no major decline 
in cell edema in the hippocampus of HI brain-
injured rabbits. Consistently, a previous study also 
reported that the combined administration of these 
medicines only elevated serotonin, among different 
factors, in the hippocampus of rats (31). 
The application of the drugs was started by the 
induction of HI brain damage; tough, the narrow 
lifespan of rabbits after HI brain damage restricted 
the follow-up of the study models to more than 
one week. The strength of data resulting from 
this animal model and their association with 
humans is also debatable. Large investigations and 
confirmatory results are needed to elucidate the 
exact effects of these drugs in HI brain damage 
conditions.
Our study demonstrated the neuroprotective 
effects of Citocoline and Piracetam in HI brain 
damage in neonatal rabbits. The animal model 
was designed to mimic perinatal asphyxia and 
HI encephalopathy in newborns. We concluded 
that regarding the low side effects of these drugs, 
Citocoline and Piracetam could be used in the 
aforementioned conditions. Citocoline could have 
priority in this regard, as our investigation showed 
the superior efficacy of this drug. However, larger 
studies and clinical trials are needed to approve the 
prescription of these drugs under HI brain injury 
circumstances.
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